Contraloid
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
4
Sites
40
Countries
6
Endpoints
37
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 37 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 8 of 37 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
3
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| PRImus-ADStudy to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) | Contraloid Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 2 | Completed | 38 | Apr 2026 | - | |
| NCT03955380MAD Phase I Study to Investigate Contraloid Acetate | Contraloid Alzheimer’s disease | Age 18-45 | Ph 1 | Completed | 1 | Apr 2019 | - | |
| NCT03944460SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate | Contraloid Alzheimer’s disease | Age 18-45 | Ph 1 | Completed | 1 | Jul 2018 | - | |
| NCT04711486Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease | Contraloid Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 1 | Completed | 1 | Jan 2022 | 1 |
Showing 1-4 of 4 trials